Lambert B, Holmberg K, Einhorn N
Hum Genet. 1984;67(1):94-8. doi: 10.1007/BF00270564.
Chromosome aberrations were studied in peripheral lymphocytes from 50 patients treated with melphalan against ovarian carcinoma. The chromosome analyses were carried out 4-132 months (mean 57 months) after the end of melphalan therapy. Most of the patients were studied several times during four years. The mean frequency of cells with chromosome and chromatid aberrations was 5.4% in the patients and 2.3% in an untreated control group. The highest aberration frequency (average 18%) was found in a patient who later developed gastric carcinoma. The dominating types of aberrations in the patients were chromosome exchanges occurring as single marker chromosomes or as multiple chromosome rearrangements. These types of aberrations were found in only 0.3% of the control cells as compared to 3.8% of the patient cells. Patients with a high total dose of melphalan (above 420 mg) and a long duration of the therapy (average 22.5 months) had a higher frequency of cells with aberrations (6.3%) than patients with a lower total dose (below 420 mg) and a shorter therapy (12 months) (4.2%). No additive effect of radiation therapy was observed on the aberration frequency.
对50例接受美法仑治疗卵巢癌的患者外周淋巴细胞中的染色体畸变进行了研究。染色体分析在美法仑治疗结束后4 - 132个月（平均57个月）进行。大多数患者在四年内接受了多次研究。患者中出现染色体和染色单体畸变的细胞平均频率为5.4%，未治疗的对照组为2.3%。在一名后来患胃癌的患者中发现了最高的畸变频率（平均18%）。患者中主要的畸变类型是作为单条标记染色体或多条染色体重排出现的染色体交换。与患者细胞的3.8%相比，这些畸变类型在对照细胞中仅占0.3%。美法仑总剂量高（超过420毫克）且治疗时间长（平均22.5个月）的患者，其畸变细胞频率（6.3%）高于美法仑总剂量低（低于420毫克）且治疗时间短（12个月）的患者（4.2%）。未观察到放射治疗对畸变频率有累加效应。
